A few examples. Eli Lilly (Zyprexa): $36B sales vs. $1.4B fine, Pfizer (Bextra & others): $16.8B vs. $2.3B, Pfizer (Neurontin): $2.12B vs. $430M, Johnson & Johnson (Risperdal): $10.8B vs. $2.2B, Amgen (Aranesp): $7.4B vs. $762M, GlaxoSmithKline (Paxil & Wellbutrin): $9B vs. $3B
Wonder where GLP-1s will end up